These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37106259)

  • 41. Distinct Clinical and Radiographic Phenotypes in Pediatric Patients With Moyamoya.
    Kaseka ML; Slim M; Muthusami P; Dirks PB; Westmacott R; Kassner A; Bhathal I; Williams S; Shroff M; Logan W; Moharir M; MacGregor DL; Pulcine E; deVeber GA; Dlamini N
    Pediatr Neurol; 2021 Jul; 120():18-26. PubMed ID: 33962345
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Revascularization of Hemorrhagic Moyamoya Disease in a North American Cohort: The Role of Timing in Perioperative and Long-Term Outcomes.
    Xu R; Xie ME; Feghali J; Yang W; Kim J; Lee R; Liew J; Tamargo RJ; Huang J
    Neurosurgery; 2022 Apr; 90(4):434-440. PubMed ID: 35060956
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and Safety of Antiplatelet Agents for Adult Patients With Ischemic Moyamoya Disease.
    Ye F; Li J; Wang T; Lan K; Li H; Yin H; Guo T; Zhang X; Yang T; Liang J; Wu X; Li Q; Sheng W
    Front Neurol; 2020; 11():608000. PubMed ID: 33519687
    [No Abstract]   [Full Text] [Related]  

  • 44. Efficacy of Surgical Treatment on the Recurrent Stroke Prevention for Adult Patients With Hemorrhagic Moyamoya Disease.
    Wang G; Zhang X; Feng M; Liu X; Guo F
    J Craniofac Surg; 2017 Nov; 28(8):2113-2116. PubMed ID: 29088693
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of Prior Antiplatelet Therapy on Outcomes After Endovascular Therapy for Acute Stroke: Endovascular Treatment in Ischemic Stroke Registry Results.
    Couture M; Finitsis S; Marnat G; Richard S; Bourcier R; Constant-Dits-Beaufils P; Dargazanli C; Arquizan C; Mazighi M; Blanc R; Eugène F; Vannier S; Spelle L; Denier C; Touzé E; Barbier C; Saleme S; Macian F; Rosso C; Clarençon F; Naggara O; Turc G; Ozkul-Wermester O; Papagiannaki C; Viguier A; Cognard C; Lebras A; Evain S; Wolff V; Pop R; Timsit S; Gentric JC; Bourdain F; Veunac L; Lapergue B; Consoli A; Gory B; Sibon I;
    Stroke; 2021 Dec; 52(12):3864-3872. PubMed ID: 34538083
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of Hyperthyroidism and Thyroid Autoantibodies with Moyamoya Disease and Its Stroke Event: A Population-based Case-control Study and Meta-analysis.
    Ahn JH; Jeon JP; Kim JE; Ha EJ; Cho WS; Park YJ; Cho NH; Choi HS; Kang HS; Son YJ; Bang JS; Oh CW
    Neurol Med Chir (Tokyo); 2018 Mar; 58(3):116-123. PubMed ID: 29353860
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Results of Conservative Follow-up or Surgical Treatment of Moyamoya Patients Who Present without Hemorrhage, Transient Ischemic Attack, or Stroke.
    Luo R; Gao F; Deng X; Zhang D; Zhang Y
    World Neurosurg; 2017 Dec; 108():683-689. PubMed ID: 28927919
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: a nationwide retrospective cohort study (J-ASPECT study).
    Onozuka D; Hagihara A; Nishimura K; Kada A; Nakagawara J; Ogasawara K; Ono J; Shiokawa Y; Aruga T; Miyachi S; Nagata I; Toyoda K; Matsuda S; Suzuki A; Kataoka H; Nakamura F; Kamitani S; Nishimura A; Kurogi R; Sayama T; Iihara K;
    BMJ Open; 2016 Mar; 6(3):e009942. PubMed ID: 27008684
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk profile in extracranial/intracranial bypass surgery--the role of antiplatelet agents, disease pathology, and surgical technique in 168 direct revascularization procedures.
    Schubert GA; Biermann P; Weiss C; Seiz M; Vajkoczy P; Schmiedek P; Thomé C
    World Neurosurg; 2014 Nov; 82(5):672-7. PubMed ID: 23838364
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Encephaloduroarteriosynangiosis for pediatric moyamoya disease: long-term follow-up of 100 cases at a single center.
    Zhang Y; Bao XY; Duan L; Yang WZ; Li DS; Zhang ZS; Han C; Zhao F; Zhang Q; Wang QN
    J Neurosurg Pediatr; 2018 Aug; 22(2):173-180. PubMed ID: 29856299
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of Operative and Conservative Treatment for Asymptomatic Moyamoya Disease: Preliminary Experience in Small Retrospective Series.
    Zeng H; Guo Y; Li Y; Yu X; Yan F; Tan X; Xu H; Peng Y; Zhuang J; Zhou H; Fu X; Wang L; Chen G
    World Neurosurg; 2021 Feb; 146():e955-e960. PubMed ID: 33217589
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differing Surgical Outcomes in a Multiethnic Cohort Suggest Racial Phenotypes in Moyamoya Disease.
    Feghali J; Xu R; Yang W; Liew J; Tamargo RJ; Marsh EB; Huang J
    World Neurosurg; 2019 Aug; 128():e865-e872. PubMed ID: 31082553
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Impact of Antiplatelet Use on the Risk of Intracerebral Hemorrhage in Patients with Alzheimer's Disease: A Nationwide Cohort Study.
    Lee TL; Liu CH; Chang YM; Lin TY; Chien CY; Chen CH; Tsai KJ; Lin SH; Sung PS
    J Alzheimers Dis; 2020; 73(1):297-306. PubMed ID: 31771060
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term outcomes of moyamoya disease versus atherosclerosis-associated moyamoya vasculopathy using high-resolution MR vessel wall imaging.
    Lu M; Zhang H; Liu S; Liu D; Peng P; Hao F; Yuan F; Liu Y; Sheng F; Zhang L; Zhao X; He Y; Han C; Cai J
    J Neurol Neurosurg Psychiatry; 2023 Jul; 94(7):567-574. PubMed ID: 36868848
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of apolipoprotein E gene polymorphism with small-vessel lesions and stroke type in moyamoya disease: a preliminary study.
    Jang DK; Huh PW; Lee KS
    J Neurosurg; 2016 Jun; 124(6):1738-45. PubMed ID: 26566210
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiplatelet Therapy in Primary Spontaneous and Oral Anticoagulation-Associated Intracerebral Hemorrhage.
    Sprügel MI; Kuramatsu JB; Gerner ST; Sembill JA; Beuscher VD; Hagen M; Roeder SS; Lücking H; Struffert T; Dörfler A; Schwab S; Huttner HB
    Stroke; 2018 Nov; 49(11):2621-2629. PubMed ID: 30355188
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prior antiplatelet therapy is not associated with larger hematoma volume or hematoma growth in intracerebral hemorrhage.
    van Ginneken V; Engel P; Fiebach JB; Audebert HJ; Nolte CH; Rocco A
    Neurol Sci; 2018 Apr; 39(4):745-748. PubMed ID: 29441487
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of intracranial vessel wall enhancement and cerebral hemorrhage in moyamoya disease: a high-resolution magnetic resonance imaging study.
    Lu M; Zhang H; Liu D; Liu X; Zhang L; Peng P; Yuan F; Liu S; Sheng F; Liu Y; He Y; Zhao X; Zhang Q; Fu H; Han C; Cai J
    J Neurol; 2021 Dec; 268(12):4768-4777. PubMed ID: 33956201
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Moyamoya disease presenting with subarachnoid hemorrhage: Clinical features and neuroimaging of a case series.
    Wan M; Han C; Xian P; Yang WZ; Li DS; Duan L
    Br J Neurosurg; 2015; 29(6):804-10. PubMed ID: 26313681
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Primary central nervous system vasculitis and moyamoya disease: similarities and differences.
    Kraemer M; Berlit P
    J Neurol; 2010 May; 257(5):816-9. PubMed ID: 20037765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.